Road to 2025: DXB helping to treat kidney and respiratory disease

Stockheads

16 Jan

Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.

Dimerix (ASX:DXB) is working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS), a second licensing deal and regulatory and ethics approval for their clinical trials.

Tune in to find out what to look out for in 2025.

This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.

Explore More

Investor Guide: Health & Biotech FY2025 featuring Tim Boreham

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2503607979"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2503607979\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2503607979?lang=en_US&edition=fundamental","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/12/DMX-1200x675-1-640x360.jpg","is_english":true,"pubTime":"2025-01-16 09:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2503607979","market":"hk","top_or_hot":-1,"title":"Road to 2025: DXB helping to treat kidney and respiratory disease","media":"Stockheads","content":"<html><body><div><div></div></div><p>Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.</p><p><strong>Dimerix (ASX:DXB)</strong> is <span>working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS), a second licensing deal and regulatory and ethics approval for their clinical trials. </span></p><p>Tune in to find out what to look out for in 2025.</p><p><i>This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.</i></p><p><i>The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.</i></p><div></div><div> <h2>Explore More</h2> <ul><li> <img decoding=\"async\" height=\"169\" sizes=\"(max-width: 300px) 100vw, 300px\" src=\"https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-300x169.jpg\" srcset=\"https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-300x169.jpg 300w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-1024x576.jpg 1024w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-768x432.jpg 768w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1-640x360.jpg 640w, https://stockhead.com.au/wp-content/uploads/2024/08/Health-and-Biotech-Investor-Guide-1200x675-1.jpg 1200w\" width=\"300\"/> <span>Investor Guide: Health &amp; Biotech FY2025 featuring Tim Boreham</span> </li> </ul></div><div></div></body></html>","source":"stockheads_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Road to 2025: DXB helping to treat kidney and respiratory disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRoad to 2025: DXB helping to treat kidney and respiratory disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-16 09:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://stockhead.com.au/stockhead-tv/road-to-2025-dxb-helping-to-treat-kidney-and-respiratory-disease/><strong>Stockheads</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.Dimerix (ASX:DXB) is working to improve the lives of ...</p>\n\n<a href=\"https://stockhead.com.au/stockhead-tv/road-to-2025-dxb-helping-to-treat-kidney-and-respiratory-disease/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DXB","symbol_name":"Deutsche Bank Contingent Capital","start_time":0,"source_url":"https://stockhead.com.au/stockhead-tv/road-to-2025-dxb-helping-to-treat-kidney-and-respiratory-disease/","article_id":"2503607979","we_media_id":null,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/12/DMX-1200x675-1-640x360.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2503607979","pubTimestamp":1736989984,"columns":[],"sourceInfo":{"source_id":"stockheads_stock","name":"Stockheads"},"weMediaInfo":null,"summary":"Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.Dimerix  is working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis , a second licensing deal and regulatory and ethics approval for their clinical trials.Tune in to find out what to look out for in 2025.This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Explore More   Investor Guide: Health & Biotech FY2025 featuring Tim Boreham","collect":0,"end_time":0,"defaultTopTitle":"stockhead.com.au","property":[],"viewcount":null,"language":"en","relate_stocks":{"DXB":"Deutsche Bank Contingent Capital","FSGS":"First Trust SMID Growth Strength ETF"},"translate_title":"2025年之路：DXB帮助治疗肾脏和呼吸系统疾病","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DXB":1,"FSGS":1},"content_text":"Stockhead’s Road to 2025 video series highlights companies’ key 2024 achievements and the routes they’re plotting towards a successful year ahead.Dimerix (ASX:DXB) is working to improve the lives of patients with inflammatory diseases, including both kidney and respiratory diseases. In this episode, Sarah Hughan covers DXB’s ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS), a second licensing deal and regulatory and ethics approval for their clinical trials. Tune in to find out what to look out for in 2025.This video was developed in collaboration with Dimerix, a Stockhead advertiser at the time of publishing.The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions. Explore More   Investor Guide: Health & Biotech FY2025 featuring Tim Boreham","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}